What cardiovascular defect does my prenatal mouse mutant have, and why?
Article first published online: 19 NOV 2002
Copyright © 2003 Wiley-Liss, Inc.
Volume 35, Issue 1, pages 1–21, January 2003
How to Cite
Conway, S. J., Kruzynska-Frejtag, A., Kneer, P. L., Machnicki, M. and Koushik, S. V. (2003), What cardiovascular defect does my prenatal mouse mutant have, and why?. Genesis, 35: 1–21. doi: 10.1002/gene.10152
- Issue published online: 19 NOV 2002
- Article first published online: 19 NOV 2002
- Manuscript Accepted: 26 JUL 2002
- Manuscript Received: 22 MAR 2002
- National Institutes of Health. Grant Numbers: HL66993, HL60104
- AHA. Grant Number: 0255460B
Summary: Since the advent of mouse targeted mutations, gene traps, an escalating use of a variety of complex transgenic manipulations, and large-scale chemical mutagenesis projects yielding many mutants with cardiovascular defects, it has become increasingly evident that defects within the heart and vascular system are largely responsible for the observed in utero lethality of the embryo and early fetus. If a transgenically altered embryo survives implantation but fails to be born, it usually indicates that there is some form of lethal cardiovascular defect present. A number of embryonic organ and body systems, including the central nervous system, gut, lungs, urogenital system, and musculoskeletal system appear to have little or no survival value in utero (Copp, 1995). Cardiovascular abnormalities include the failure to establish an adequate yolk-sac vascular circulation, which results in early lethality (E8.5–10.5); poor cardiac function (E9.0–birth); failure to undergo correct looping and chamber formation of the primitive heart tube (E9.0–11.0); improper septation, including division of the common ventricle and atria and the establishment of a divided outflow tract (E11.0–13.0); inadequate establishment of the cardiac conduction system (E12.0–birth); and the failure of the in utero cardiovascular system to adapt to adult life (birth) and close the interatrial and aorta-pulmonary trunk shunts that are required for normal fetal life. Importantly, the developmental timing of lethality is usually a good indicator of both the type of the cardiovascular defect present and may also suggest the possible underlying cause/s. The purpose of this review is both to review the literature and to provide a beginner's guide for analysing cardiovascular defects in mouse mutants. genesis 35:1–21, 2003. © 2002 Wiley-Liss, Inc.